Perceptions and Experiences of Patients Receiving Oral Chemotherapy

被引:49
作者
Simchowitz, Brett [2 ]
Shiman, Lawrence
Spencer, Justin
Brouillard, Daniela [1 ]
Gross, Anne [1 ]
Connor, Maureen [3 ]
Weingart, Saul N. [1 ]
机构
[1] Dana Farber Canc Inst, Adult Ambulatory Serv, Boston, MA 02115 USA
[2] Univ Calif San Francisco, Sch Med, San Francisco, CA USA
[3] Qual & Patient Safety Consultant, Arlington, MA USA
基金
美国医疗保健研究与质量局;
关键词
METASTATIC COLORECTAL-CANCER; INTRAVENOUS FLUOROURACIL; LEUCOVORIN; THERAPY; CAPECITABINE;
D O I
10.1188/10.CJON.447-453
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although many patients prefer orally administered cancer therapy (including oral chemotherapy) because of its convenience, the shift from hospital to home-based administration creates concerns. This article explores the perceptions and experiences of oral chemotherapy users and their caregivers to assess vulnerabilities and improvement opportunities at each stage of the medication process: choosing oral chemotherapy, prescribing, dispensing, administering, and monitoring. The authors recruited 15 current and former oral chemotherapy users, as well as caregivers who administered the medications to children, to participate in one of two focus group sessions at a comprehensive cancer center. Participants largely were satisfied with oral cancer therapy but raised concerns regarding their lack of preparedness for side effects and their unfamiliarity with the possible techniques to mitigate drug toxicity. Participants also described difficulties obtaining medications through retail pharmacies. Parents of pediatric patients with cancer indicated concerns regarding their children's emotional health and correct medication administration. Participants believed that the initial prescribing encounter should have included more education, and they also wanted more frequent follow-up by healthcare practitioners. As oral cancer therapy is used more widely, oncology healthcare providers will need to create robust mechanisms to support their safe use.
引用
收藏
页码:447 / 453
页数:7
相关论文
共 20 条
  • [1] Overview of the changing paradigm in cancer treatment: Oral chemotherapy
    Aisner, Joseph
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2007, 64 : S4 - S7
  • [2] Birner Ann, 2003, Clin J Oncol Nurs, V7, P158, DOI 10.1188/03.CJON.158-162
  • [3] Borner M, 2001, ONCOLOGIST, V6, P12
  • [4] Patient preference and pharmacokinetics of oral modulated UFT versus intravenous fluorouracil and leucovorin:: a randomised crossover trial in advanced colorectal cancer
    Borner, MM
    Schöffski, P
    de Wit, R
    Caponigro, F
    Comella, G
    Sulkes, A
    Greim, G
    Peters, GJ
    van der Born, K
    Wanders, J
    de Boer, RF
    Martin, C
    Fumoleau, P
    [J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 (03) : 349 - 358
  • [5] First-line oral capecitabine therapy in metastatic colorectal cancer:: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin
    Cassidy, J
    Twelves, C
    Van Cutsem, E
    Hoff, P
    Bajetta, E
    Boyer, M
    Bugat, R
    Burger, U
    Garin, A
    Graeven, U
    McKendrick, J
    Maroun, J
    Marshall, J
    Osterwalder, B
    Pérez-Manga, G
    Rosso, R
    Rougier, P
    Schilsky, RL
    [J]. ANNALS OF ONCOLOGY, 2002, 13 (04) : 566 - 575
  • [6] Oral vinorelbine: Feasibility and safety profile
    Depierre, A
    Freyer, G
    Jassem, J
    Orfeuvre, H
    Ramlau, R
    Lemarie, E
    Koralewski, P
    Mauriac, L
    Breton, JL
    Delozier, T
    Trillet-Lenoir, V
    [J]. ANNALS OF ONCOLOGY, 2001, 12 (12) : 1677 - 1681
  • [7] Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer
    Douillard, JY
    Hoff, PM
    Skillings, JR
    Eisenberg, P
    Davidson, N
    Harper, P
    Vincent, MD
    Lembersky, BC
    Thompson, S
    Maniero, A
    Benner, SE
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (17) : 3605 - 3616
  • [8] Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: Results of a randomized phase III study
    Hoff, PM
    Ansari, R
    Batist, G
    Cox, J
    Kocha, W
    Kuperminc, M
    Maroun, J
    Walde, D
    Weaver, C
    Harrison, E
    Burger, HU
    Osterwalder, B
    Wang, AO
    Wong, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (08) : 2282 - 2292
  • [9] LEBOVITS AH, 1990, CANCER-AM CANCER SOC, V65, P17, DOI 10.1002/1097-0142(19900101)65:1<17::AID-CNCR2820650106>3.0.CO
  • [10] 2-I